Perbak Capital Partners’s United Therapeutics UTHR Stock Holding History

Perbak Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,438	Closed	-$853K	–	244
2026 Q1	$853K	Buy	+1,438	New	+$716K	0.21%	97
2025 Q4	–	Sell	-1,903	Closed	-$798K	–	320
2025 Q3	$798K	Buy	1,903 +1,180	+163%	+$397K	0.14%	163
2025 Q2	$208K	Buy	+723	New	+$216K	0.05%	271

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Perbak Capital Partners's UTHR Position: Q2 2026 in Review

Perbak Capital Partners sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 1,438 shares — an estimated $853K sold.

Perbak Capital Partners first reported a position in UTHR in Q2 2025 and held it in 3 quarters. The position peaked at $853K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Perbak Capital Partners reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Perbak Capital Partners sold 1,438 United Therapeutics shares in Q2 2026, an estimated $853K.
Perbak Capital Partners first reported a position in United Therapeutics in Q2 2025 and held it in 3 quarters.
Perbak Capital Partners's United Therapeutics position peaked at $853K in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.